Mirvetuximab Soravtansine
drugOn this page
Also known as ElahereIMGN-853IMGN853Mirvetuximab soravtansinaMirvetuximab soravtansine gynxMirvetuximab soravtansine-gynx
Summary
Mirvetuximab Soravtansine (CHEMBL3545132) is an approved antibody drug conjugate (ATC L01FX26) targeting FOLR1; indicated across 7 conditions including neoplasm and peritoneal neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody drug conjugate
- ATC class: L01FX26
- Targets: 1 (FOLR1)
- Indications: 7 conditions
- Clinical trials: 21
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3545132 |
| Name | Mirvetuximab Soravtansine |
| Type | Antibody drug conjugate |
| Max phase | 4 |
| ATC | L01FX26 |
Also known as: Elahere, IMGN-853, IMGN853, Mirvetuximab soravtansina, Mirvetuximab soravtansine, Mirvetuximab soravtansine gynx, Mirvetuximab soravtansine-gynx, MIRVETUXIMAB SORAVTANSINE
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| FOLR1 | folate receptor alpha | Binding | 10.1 | 0.2% | P15328 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): FOLR1.
Top Reactome pathways
3 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| COPII-mediated vesicle transport | 1 | FOLR1 |
| Cargo concentration in the ER | 1 | FOLR1 |
| COPI-mediated anterograde transport | 1 | FOLR1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| heart looping | 1 |
| neural crest cell migration involved in heart formation | 1 |
| cardiac neural crest cell migration involved in outflow tract morphogenesis | 1 |
| receptor-mediated endocytosis | 1 |
| cell adhesion | 1 |
| fusion of sperm to egg plasma membrane involved in single fertilization | 1 |
| folic acid transport | 1 |
| regulation of transforming growth factor beta receptor signaling pathway | 1 |
| axon regeneration | 1 |
| sperm-egg recognition | 1 |
| tetrahydrofolate biosynthetic process | 1 |
| folic acid metabolic process | 1 |
| regulation of canonical Wnt signaling pathway | 1 |
| pharyngeal arch artery morphogenesis | 1 |
| anterior neural tube closure | 1 |
Indications & clinical
Indications
7 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| peritoneal neoplasm | 4 | MONDO:0006901 | EFO:1001100 |
| fallopian tube neoplasm | 4 | MONDO:0021092 | MONDO:0021092 |
| endometrium neoplasm | 2 | MONDO:0021251 | MONDO:0011962 |
| triple-negative breast carcinoma | 2 | MONDO:0005494 | EFO:0005537 |
| breast neoplasm | 1 | MONDO:0021100 | MONDO:0007254 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 21.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 12 |
| PHASE3 | 4 |
| PHASE1 | 4 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02631876 | PHASE3 | COMPLETED | A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer |
| NCT04209855 | PHASE3 | COMPLETED | A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression |
| NCT04296890 | PHASE3 | COMPLETED | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression |
| NCT05622890 | PHASE3 | UNKNOWN | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer |
| NCT03832361 | PHASE2 | RECRUITING | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer |
| NCT03835819 | PHASE2 | ACTIVE_NOT_RECRUITING | A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) |
| NCT04274426 | PHASE2 | ACTIVE_NOT_RECRUITING | Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer |
| NCT05456685 | PHASE2 | ACTIVE_NOT_RECRUITING | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer |
| NCT05887609 | PHASE2 | RECRUITING | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib |
| NCT06365853 | PHASE2 | RECRUITING | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression |
| NCT06682988 | PHASE2 | RECRUITING | A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine |
| NCT06890338 | PHASE2 | RECRUITING | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. |
| NCT07059845 | PHASE2 | RECRUITING | A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer |
| NCT02606305 | PHASE1/PHASE2 | COMPLETED | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT03106077 | PHASE2 | COMPLETED | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer |
| NCT03836157 | PHASE2 | WITHDRAWN | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer |
| NCT05041257 | PHASE2 | COMPLETED | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers |
| NCT01609556 | PHASE1 | COMPLETED | First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors |
| NCT02996825 | PHASE1 | COMPLETED | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer |
| NCT03045393 | PHASE1 | WITHDRAWN | Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC |
| NCT03552471 | PHASE1 | COMPLETED | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
5 molecules share ≥1 primary target. Top 5 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| METHOTREXATE | ChEMBL + PubChem | Phase 4 (approved) | FOLR1 |
| PEMETREXED | ChEMBL + PubChem | Phase 4 (approved) | FOLR1 |
| PRALATREXATE | ChEMBL + PubChem | Phase 4 (approved) | FOLR1 |
| RALTITREXED | ChEMBL | Phase 4 (approved) | FOLR1 |
| Folic Acid | PubChem | Approved | FOLR1 |
Related Atlas pages
- Genes: FOLR1
- Diseases: neoplasm, peritoneal neoplasm, fallopian tube neoplasm
- Drugs: Methotrexate, Pemetrexed, Pralatrexate, Raltitrexed, Folic Acid